VICTORIA
2020
Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction
In 5,050 patients with worsening HFrEF (EF < 45%), vericiguat reduced cardiovascular death or first heart-failure hospitalisation compared with placebo.
Result
Efficacy: Composite of death from cardiovascular causes or first hospitalisation for heart failureHR 0.90 (95% CI 0.82-0.98) · P = 0.02
Below 1 favours vericiguat, above 1 favours placebo.
- Absolute difference
- 3.0 points
- NNT
- 34
Absolute difference and NNT are derived from the event rates.
Also reported: Over median 10.8 months.
- Subtopic
- sGC stimulator
- Design
- Double-blind placebo-controlled RCT, phase 3
- Relevance
- Supporting: context rather than must-know.
- Cited in
- ESC 2021 HFAHA/ACC 2022 HF
- Source
- Armstrong PW, et al. N Engl J Med. 2020;382(20):1883-1893.doi 10.1056/NEJMoa1915928
Discussion & critique
Modest relative benefit in a very high-risk, recently decompensated cohort, with no reduction in CV death alone. Added an oral soluble guanylate cyclase stimulator as an option for worsening HFrEF.